8,925 Shares in Xenon Pharmaceuticals Inc. $XENE Acquired by Capstone Investment Advisors LLC

Capstone Investment Advisors LLC purchased a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 8,925 shares of the biopharmaceutical company’s stock, valued at approximately $539,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Goldman Sachs Group Inc. increased its stake in shares of Xenon Pharmaceuticals by 7.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company’s stock valued at $14,854,000 after acquiring an additional 32,486 shares during the last quarter. Jump Financial LLC acquired a new position in Xenon Pharmaceuticals during the second quarter worth approximately $532,000. Sei Investments Co. purchased a new position in Xenon Pharmaceuticals during the second quarter worth approximately $711,000. The Manufacturers Life Insurance Company acquired a new position in shares of Xenon Pharmaceuticals in the 2nd quarter valued at $816,000. Finally, Alliancebernstein L.P. grew its stake in shares of Xenon Pharmaceuticals by 14.2% during the 2nd quarter. Alliancebernstein L.P. now owns 1,518,527 shares of the biopharmaceutical company’s stock valued at $47,530,000 after buying an additional 189,141 shares during the period. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Insider Transactions at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the sale, the director owned 1,455 shares in the company, valued at $77,318.70. This trade represents a 44.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steven Gannon sold 10,000 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $64.06, for a total value of $640,600.00. Following the sale, the director owned 1,870 shares in the company, valued at $119,792.20. This represents a 84.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 12,512 shares of company stock valued at $774,088. 2.91% of the stock is currently owned by insiders.

Xenon Pharmaceuticals Trading Down 3.1%

NASDAQ XENE opened at $59.99 on Friday. The stock has a market cap of $5.80 billion, a P/E ratio of -12.66 and a beta of 0.62. The company’s fifty day simple moving average is $63.18 and its 200-day simple moving average is $56.39. Xenon Pharmaceuticals Inc. has a 52 week low of $35.60 and a 52 week high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.05. During the same quarter last year, the business earned ($1.07) EPS. On average, research analysts expect that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on XENE shares. Needham & Company LLC dropped their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Wells Fargo & Company reissued an “overweight” rating and set a $69.00 target price on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Royal Bank Of Canada reduced their price target on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating on the stock in a research report on Friday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. Finally, HC Wainwright restated a “buy” rating and set a $74.00 target price on shares of Xenon Pharmaceuticals in a report on Monday, August 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $77.13.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.